Pharma channel feed – Endpoints News

Pharma channel feed

Versant has a new obesity biotech. AstraZeneca has the option to buy it

12 months ago

Novo Nordisk looks beyond weight loss and diabetes to expand in new illnesses

12 months ago

Senators strike bipartisan tone on more pharma patent reforms

12 months ago

Sen. Wyden questions Pfizer over tax rate as part of ongoing investigation

12 months ago

With $5B in China sales, AstraZeneca doubles down on Chinese biopharma innovation

12 months ago

Bristol Myers' subcutaneous version of Opdivo gets earlier PDUFA date

12 months ago

AstraZeneca counts on ‘difficult-to-copy’ therapies for big 2030 goal and beyond

12 months ago

‘A new era of growth’: AstraZeneca aims for $80B revenue, 20 new drugs by 2030

12 months ago

FDA withdraws Helsinn’s accelerated approval for cancer drug after company’s request

12 months ago

Jury says AstraZeneca should pay Pfizer $107M+ over Tagrisso infringement

12 months ago

PTC's muscular dystrophy drug Translarna to get another review in the EU

12 months ago

FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea

12 months ago

Study identifies groups of people who mistrust the FDA

12 months ago

Moderna scores European victory over Pfizer and BioNTech in mRNA patent battle

12 months ago

EMA's safety committee recommends suspending preterm birth drugs

12 months ago

Q&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs

12 months ago

FDA approves Amgen’s T cell engager in aggressive form of lung cancer

Last year

GSK plans to sell off remaining stake in consumer spinout Haleon

Last year

Pharma is rethinking how it interacts with patients after Eli Lilly ripped up the playbook

Last year

Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew

Last year

House panel advances bills targeting rare disease, priority review vouchers

Last year

Bristol Myers' CAR-T therapy Breyanzi adds follicular lymphoma to list of approvals

Last year

GSK, UK government budget £130M to fight global antimicrobial resistance

Last year

BeiGene looks at new partnerships, with a full cancer pipeline and growing footprint

Last year

First page Previous page 52 53 545556 57 58 Next page Last page